Management tracks: Clearside, ImCheck

Clearside Biomedical Inc. (NASDAQ:CLSD) hired Leslie Zacks as general counsel and chief compliance officer. He was VP, general counsel and chief compliance officer at Arbor Pharmaceuticals Inc. (Atlanta, Ga.). Clearside plans to submit an NDA for lead candidate Zuprata (CLS-TA) to treat macular edema by year end. Zuprata is a suspension of triamcinolone acetonide delivered using the company's suprachoroidal space microinjector.

Immunotherapy company ImCheck Therapeutics S.A.S. (Marseille, France) hired René Hoet as CSO. He was VP of biologics research at Bayer AG (Xetra:BAYN), where his team was responsible for antibody lead discovery and optimization. ImCheck plans to bring its two lead antibody programs to the clinic by 2020...